TrovaGene (TROV) Announces Quarterly Earnings Results

TrovaGene (NASDAQ:TROV) released its quarterly earnings results on Wednesday. The medical research company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.15, Fidelity Earnings reports. The company had revenue of $0.09 million during the quarter. TrovaGene had a negative return on equity of 188.93% and a negative net margin of 2,970.66%.

Shares of NASDAQ:TROV traded up $0.01 during midday trading on Thursday, reaching $0.78. The company’s stock had a trading volume of 400 shares, compared to its average volume of 2,484,623. The company has a market cap of $13.27 million, a P/E ratio of -0.12 and a beta of 0.14. TrovaGene has a 1 year low of $0.65 and a 1 year high of $8.64.

Several equities analysts have weighed in on TROV shares. Zacks Investment Research raised TrovaGene from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. Maxim Group reissued a “buy” rating on shares of TrovaGene in a research report on Monday, August 6th. Finally, ValuEngine raised TrovaGene from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $4.75.

WARNING: “TrovaGene (TROV) Announces Quarterly Earnings Results” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/11/08/trovagene-trov-announces-quarterly-earnings-results.html.

About TrovaGene

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Featured Article: Capital gains and your 401(k) or IRA

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply